CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...

Chronic myeloid leukaemia (CML) can be considered, for some aspects, a model for malignant tumours that evolve through a multi-step pathogenetic process. In its natural history, CML is usually ...